News | March 13, 2009

BridgePoint Medical Completes First U.S. Clinical Case Using CrossBoss, Stingray Devices in CTO Procedure

March 13, 2009 - BridgePoint Medical Inc. completed the first human clinical case in the U.S. using its CrossBoss CTO Catheter and Stingray CTO Re-Entry System.

The CrossBoss CTO Catheter and Stingray CTO Re-Entry System are under clinical investigation to demonstrate safety and effectiveness in the treatment of completely blocked arteries known as chronic total occlusions (CTO). BridgePoint Medical's clinical trial, Facilitated Antegrade Steering Technique for Chronic Total Occlusions (FAST-CTOs), was conditionally approved in January 2009 by the FDA.

The first clinical case was completed by William Lombardi, M.D., interventional cardiologist and cardiac catheterization lab director at North Cascade Cardiology in Bellingham, WA. The patient was a 61-year-old woman with a chronic total occlusion of her right coronary artery, chest pain (characterized as level three angina) and a positive stress test. The patient was referred to Dr. Lombardi for inclusion in BridgePoint Medical's FAST-CTOs clinical trial after a failed treatment attempt to cross the lesion by a referring physician.

Procedural completion took 35 minutes, resulting in the opening of the completely blocked vessel and return of normal blood flow to the patient's heart. "The BridgePoint Medical System allowed me to open this challenging total occlusion," Dr. Lombardi said. "BridgePoint Medical's clinical trial is designed to demonstrate the CrossBoss CTO Catheter and the Stingray Re-Entry System are broadly effective in re-establishing blood flow across completely blocked arteries and these devices will hopefully provide improved options for patient care."

The patient was released from the hospital the day after the procedure.

Annually 1.3 million worldwide patients suffer from chronic total occlusions of coronary arteries. Interventional cardiologists are currently unable to broadly treat patients with chronic total occlusions, which comprise approximately one third of all patients diagnosed with coronary artery disease. For these patients, a common alternative is open heart bypass surgery or palliative medical care.

For more information: www.bridgepointmedical.com

Related Content

Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
The LimFlow Percutaneous Deep Vein Arterialization System (pDVA) converts veins into arteries to restore blood flow in critical limb ischemia (CLI).

The LimFlow Percutaneous Deep Vein Arterialization System (pDVA) converts veins into arteries to restore blood flow in critical limb ischemia (CLI). This image shows how the covered stents used with the system connect to create a new arterial pathway.

News | Peripheral Artery Disease (PAD)| August 02, 2017
Aug.
Philips Announces Relaunch of Pioneer Plus IVUS-Guided Catheter
News | Chronic Total Occlusion (CTO)| June 28, 2017
June 28, 2017 — Royal Philips recently announced the relaunch of its Pioneer Plus...
PCI, drugs, medication, fully blocked arteries, chronic total occlusion, ACC.17, clinical study
News | Chronic Total Occlusion (CTO)| March 29, 2017 | Dave Fornell
March 29, 2017 — In patients with a complete, persistent arterial blockage, medication alone was found to be equal to
Siemens Healthineers, ACC 2017, syngot CTO Guidance, Compressed Sensing Cardiac Cine
News | Cardiac Imaging| March 16, 2017
During the 66th Annual Scientific Session & Expo of the American College of Cardiology (ACC), March 17-19 in...
Teleflex, FDA 510k clearance, TrapLiner Catheter, U.S. launch
Technology | Catheters| March 02, 2017
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
Technology | Radial Access| February 17, 2017
Medtronic plc announced that its coronary portfolio will now include the DxTerity Diagnostic Angiography Catheter line...
Mercator MedSystems, DANCE trial data, ISET, LINC, Bullfrog Micro-Infusion Device
News | Peripheral Artery Disease (PAD)| February 15, 2017
Mercator MedSystems announced that the national co-principal investigators of the company’s DANCE trial each presented...
Vascular Solutions, Teleflex
Feature | December 07, 2016
December 7, 2016 — Teleflex Inc. and Vascular Solutions Inc.
Overlay Init